Intuitive Surgical (NASDAQ:ISRG) Shares Down 1.2%

Intuitive Surgical, Inc. (NASDAQ:ISRG) shares traded down 1.2% on Tuesday . The stock traded as low as $485.79 and last traded at $486.60. 211,410 shares traded hands during trading, a decline of 86% from the average session volume of 1,513,826 shares. The stock had previously closed at $492.63.

Analyst Ratings Changes

Several research firms have recently issued reports on ISRG. Robert W. Baird increased their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Truist Financial increased their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price target for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Piper Sandler increased their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Finally, Evercore ISI cut their price objective on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Intuitive Surgical Trading Down 1.0 %

The company’s fifty day moving average is $457.57 and its two-hundred day moving average is $416.92. The stock has a market cap of $169.08 billion, a price-to-earnings ratio of 86.28, a P/E/G ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the firm earned $1.18 EPS. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. Analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,655,048.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,655,048.26. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,656 shares of company stock worth $24,700,644. Insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ISRG. Advisors Asset Management Inc. lifted its position in shares of Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after purchasing an additional 1,129 shares during the last quarter. Public Employees Retirement System of Ohio lifted its position in shares of Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after purchasing an additional 9,869 shares during the last quarter. HCR Wealth Advisors lifted its position in shares of Intuitive Surgical by 26.3% during the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after purchasing an additional 217 shares during the last quarter. Checchi Capital Advisers LLC lifted its position in shares of Intuitive Surgical by 2.5% during the 4th quarter. Checchi Capital Advisers LLC now owns 2,875 shares of the medical equipment provider’s stock worth $970,000 after purchasing an additional 70 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Intuitive Surgical by 0.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 519,807 shares of the medical equipment provider’s stock worth $175,364,000 after purchasing an additional 4,335 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.